Latent Lines

MP — MP

1.55% of the book · -3.25% since entry · entered 2025-11

Sits on

Reclassification -- T2 High Conviction (2026-05-20)

MP is reclassified from probe-treated T2 to T2 High Conviction with a formal scale-up mandate. Governing policy: MP Policy v0.1 in project/docs/PORTFOLIO_CONTEXT.md (Trading Rules section). Driver: the DoW masses-layer research (project/wiki/entities/department-of-war.md) -- six structural DoW moats (preferred equity, warrant, $150M Samarium loan, $110/kg Price Protection Agreement through 2035, 10X offtake with a $140M EBITDA floor, Maaden JV). MP Policy v0.1 sets a near-term scale-up floor and a confirmed-thesis ceiling gated on the mid-2026 separation-facility commissioning, with Anchor as the trajectory destination (not a current label).

One-line thesis

Only operating US rare earth mine and the Pentagon's chosen domestic supply chain anchor, backed by $400M DoD equity investment and a 10-year magnet offtake agreement that structurally insulates revenue from spot market volatility.

Position

  • T2 High Conviction position entered ~November 2025 (STCG profile; LTCG threshold ~November 2026 per data/cost_basis.json). Reclassified from probe treatment to T2 High Conviction 2026-05-20. Scale-up authorized under MP Policy v0.1 (project/docs/PORTFOLIO_CONTEXT.md).
  • Thesis validation gate: HREE separation-facility commissioning at Mountain Pass (guided 2026; as of 2026-06-25 not yet confirmed).

Thesis (detailed)

Mountain Pass in the Mojave Desert is the only operating rare earth mine in the United States, a status that transforms MP Materials from a commodity miner into a national security infrastructure asset. The company produces mixed rare earth carbonate (MREC) and has been systematically building separation and magnet manufacturing capability -- a full vertical integration play in a supply chain that is otherwise 85% dominated by China.

The DoD relationship is not advisory -- it is structural. The Pentagon has committed $400M in convertible preferred equity and warrants, a $150M 12-year loan, a NdPr price floor of $110/kg starting Q4 2025 (guaranteed for 10 years), and a 10-year offtake commitment for 7,000 MT/year of rare earth magnets. This is the US government explicitly designating MP as the domestic REE supply anchor under DPA Title III authorities. No other Western REE company has an arrangement of this scope or this specificity.

The separation facility commissioning (mid-2026 guided) is the next major inflection point. The move up the value chain is already underway: MP ceased all China concentrate sales in July 2025 and redirected output to NdPr oxide, metal, and magnetic precursor manufacturing at the Independence Facility (Fort Worth, TX), which commenced NdFeB permanent magnet production in December 2025 (atom 0001801368-26-000008). Rare earth concentrate revenue: $144.4M in FY2024, $42.0M in FY2025, $0 in Q1 2026 (atom 0001801368-26-000008). The next step in the value chain is the HREE separation facility at Mountain Pass. The DoD price floor removes the downside scenario of NdPr price collapse that would otherwise be the primary bear case. The remaining risk is execution: the heavy REE separation facility (dysprosium/terbium) is a technically complex expansion that has no domestic precedent at scale.

Recent catalysts (60-day rolling)

  • 2026-06-22 -- China MOFCOM entity list: China added MP Materials (alongside USAR and 8 other US defense/industrial firms) to its export-control entity list, barring Chinese exporters from supplying dual-use items to MP with extraterritorial reach on China-origin goods -- stated retaliation for the Pentagon adding ~80 Chinese firms to its military-entities list. Assessed operational impact: minimal (MP ceased all China sales July 2025; no current Chinese supplier dependencies identified). BofA reiterated Buy, $85 PT (date-stamped June 22, 2026; verify for currency). Structural paradox: being targeted validates MP as a strategically significant supply-chain threat to China. See Risks section for the state-dependence delta. Sources: Al Jazeera 2026-06-22; FDD analysis 2026-06-24.
  • 2026-06-09 -- AGM (8-K accession 0001801368-26-000035): Directors Arnold Donald and Randall Weisenburger elected through 2029; say-on-pay approved (~70.5M for / ~20.7M against, ~22.7% dissent -- mildly elevated but not at actionable opposition threshold); KPMG ratified. Low materiality governance event.
  • 2026-05-22 -- USAR lawsuit: MP filed suit in the Business Court of Texas against USA Rare Earth (USAR), ex-MP engineer Kevin Elkins, and FOM Technologies over grain-boundary-diffusion (GBD) magnet trade secrets; seeks >$5M plus injunction. USAR filed a denial June 2026. Read: GBD IP validation signal -- confirms the technology as a meaningful competitive differentiator; moderate litigation overhang. Cross-link: MP and USAR are simultaneously US-government-backed and co-named on China's June 22 entity list. Source: 2026-06-25 scout pass (citing The Oklahoman Post, 2026-05-28).
  • 2026-05-20 / 2026-06-09 -- COO insider buys: COO Michael Rosenthal purchased 17,000 sh @ $56.62 (2026-05-20, direct account; Form 4 accession 0001832050-26-000005) and 10,000 sh @ $54.30 (2026-06-09, family trust; Form 4 accession 0001832050-26-000007) -- ~$1.5M combined in 37 days, at prices consistent with the position's cost basis (see data/cost_basis.json). Conviction signal from the operating executive.
  • 2026-Q2 (ongoing) -- HREE commissioning watch: Commissioning described as "set to begin imminently" in the May 7, 2026 Q1 earnings PR (atom 0001801368-26-000027_ex). As of 2026-06-25 (~48 days later), no commissioning announcement has been made. This is the primary scale-up gate under MP Policy v0.1; the larger accumulation tranche does not fire before confirmation.
  • 2026-Q2 -- NdPr price arc: ~$53/kg (Jan 2026) -> ~$126/kg peak (~Apr 2026, above the $110/kg PPA floor) -> ~$90-100/kg (late May 2026, back below floor). Q2 2026 earnings will show a mixed pricing picture. Source: 2026-06-25 scout pass.
  • 2026-Q1 -- 10X Facility groundbreaking: Northlake, TX (120-acre site selected Feb 2026; land purchase $80M closed Apr 2026). Construction began Q1 2026. Target: 7,000 MT/yr NdFeB magnets, commissioning 2028. DoW offtake guarantees $140M annual EBITDA floor post-Production Milestone Date. Source: atom 0001801368-26-000027_ex.

Risks / What would break the thesis

  • Separation facility delayed beyond H2 2026 -- value chain upgrade thesis deferred; this is thesis-break condition #4 in MP Policy v0.1 (project/docs/PORTFOLIO_CONTEXT.md); as of 2026-06-25, no commissioning announcement despite "imminently" language in the May 7 Q1 PR (atom 0001801368-26-000027_ex)
  • DoD transaction legal durability -- the 10-K explicitly flags DPA Title III authority as "unconventional" with no assurance the transaction funding "will not be modified, challenged or impaired in the future" (atom 0001801368-26-000008, risk_factor_deltas[0]); the Q1 2026 earnings PR separately names legislative, judicial, and executive challenge as a live risk factor; this is a durability-of-legal-framework risk distinct from "administration preference"
  • China rare earth price dumping -- structurally hedged by the PPA floor ($110/kg through Dec 2035); DoW quarterly shortfall payments confirmed in Q4 2025 ($51.0M) and Q1 2026 ($42.3M); the residual risk is PPA legal durability, not spot price exposure
  • Heavy REE (Dy/Tb) technical failure at scale -- no domestic precedent for Dy/Tb separation at commercial scale; no specific commissioning quarter disclosed beyond "in 2026" (atom 0001801368-26-000029)
  • 2026-06-22 -- China MOFCOM entity list (state-dependence delta): China-as-sanctioner added MP to its export-control entity list. Operational impact assessed minimal (no current Chinese supplier dependencies; concentrate sales ceased July 2025). State-dependence assessment: prior risk was US government as financier/insurer (DoW PPA, preferred equity, loan) -- a "benefits from public spending" profile. The June 22 listing adds a new vector: foreign state targeting. The paradox is that targeting confirms strategic significance. Watch for: (a) escalation via Chinese HREE feedstock controls affecting non-US intermediaries used pre-commissioning; (b) retaliatory measures affecting Maaden JV supply-chain adjacencies. No thesis-break at this stage.
  • Capital structure overhang: 2030 Convertible Notes ($862.8M at $21.74/share) met the Stock Price Condition in Q1 2026, enabling holder-election conversions during Q2 2026 (atom 0001801368-26-000029, reported_results[33]). Full conversion = ~39.7M new shares (~22.3% dilution); Capped Call Options covering 34.4M shares up to ~$31.06 partially offset this in the $21.74-$31.06 band. Monitor Q2 10-Q for conversion activity.

Triggers

  • HREE separation-facility commissioning (primary gate, ACTIVE WATCH): No announcement as of 2026-06-25 (~48 days since "set to begin imminently," May 7 Q1 PR, atom 0001801368-26-000027_ex). Success unlocks the gated accumulation tranche per MP Policy v0.1. Failure or slip past H2 2026 fires thesis-break condition #4. This is the single highest-priority watch item.
  • Q2 2026 earnings (expect late July / early August): First full-quarter read on realized NdPr pricing (April above-floor run + late-May below-floor return produces a mixed picture), HREE commissioning status update, 10X construction progress. Management commentary on commissioning timeline is the key watch item.
  • ~November 2026 -- LTCG threshold: Position lot becomes LTCG-eligible (see data/cost_basis.json). Relevant tax-calendar trigger for scale-up timing; the accumulation mandate is unaffected but lot-date awareness matters for any ladder mechanics installed post-commissioning.
  • 2030 Convertible Notes conversion window: $862.8M at $21.74/share; Q2 2026 is an active holder-election conversion window (Stock Price Condition met Q1 2026, atom 0001801368-26-000029, reported_results[33]). Watch Q2 10-Q share count for conversion activity. Capped Call Options (~$31.06 cap) mitigate dilution only in the $21.74-$31.06 band.
  • Any DoD contract modification, Maaden JV CFIUS action, or DPA Title III legal-durability development -- any of these fires a policy review under MP Policy v0.1.
  • NdPr spot price: below $110/kg activates PPA quarterly shortfall payments (mechanism confirmed; Q4 2025 $51.0M, Q1 2026 $42.3M); above $110/kg triggers above-floor revenue mode where 30% of excess goes to DoW post-10X full production.
  • HREE prices (Dy/Tb) as forward signal: dysprosium and terbium both reportedly up ~100%+ YTD as of mid-2026 (2026-06-25 scout pass; specific per-kg levels not yet verified against a commodity data source). Rising HREE prices strengthen the forward economics of the HREE facility's Dy/Tb output; upside is latent until commissioning begins.

External authoritative sources

Open questions / hypotheses

  • ANSWERED (2026-06-25) -- DoD conversion terms: $30.03/share for both instruments: (1) Series A Preferred Stock convertible into 13,320,013 common shares; (2) 10-year warrant exercisable for up to 11,201,659 common shares. Both instruments become dilutive at and above $30.03/share. Combined potential dilution: up to ~24.5M shares from these two DoW instruments. Source: atom 0001801368-26-000008.
  • ANSWERED (2026-06-25) -- NdPr realized vs. floor: Q1 2026 implied realized NdPr price ~$70.7/kg (derived: $71.1M NdPr revenue / 1,006 MT NdPr sales, atom 0001801368-26-000029), generating $42.3M PPA income on the $110/kg shortfall. NdPr price arc through mid-2026 (2026-06-25 scout pass): ~$53/kg (Jan 2026) -> ~$126/kg peak (~Apr 2026, briefly above the $110/kg floor) -> ~$90-100/kg (late May 2026, back below floor). Q2 2026 earnings will reflect a mixed picture -- above-floor realized NdPr revenue during the April run, PPA income during the below-floor periods before and after.
  • Is the HREE (Dy/Tb) separation facility fully DoD-funded, or is there additional capex exposure? Partial answer (2026-06-25): FY2026 capex guidance is $500M-$600M net of government award proceeds, directed at the HREE facility, Independence Facility expansion, and 10X Facility purchases (atom 0001801368-26-000029, reported_results[49]). The "$35M DPA Title III grant" figure from the prior version of this question is not confirmed in any available atom -- if sourced from external research, verify against SEC filings before treating as confirmed. Q1 2026 capex alone was $77.4M.
  • Analyst coverage (date-stamped): Average sell-side target ~$76.67 as cited in MP Policy v0.1 (project/docs/PORTFOLIO_CONTEXT.md, as of 2026-05-20); BofA Buy / $85 PT reiterated 2026-06-22 (post-entity-list). Both are third-party estimates date-stamped above and should be re-verified before use. The unverified TIKR performance figure and the stale price anchor carried in the prior version of this question have been retired.
  • HREE commissioning silence (~48 days post-"imminently" Q1 PR as of 2026-06-25): has commissioning activity begun and simply not been press-released, or is there a technical delay? The H2 2026 thesis-break condition runs through Dec 31 per MP Policy v0.1; what is the buffer against a slip? Source: atom 0001801368-26-000027_ex.
  • 2030 Convertible Notes Q2 2026 conversion activity: $862.8M at $21.74/share; Q2 2026 was an active holder-election window. Did any conversions occur? What is the current outstanding principal? Above $31.06 the Capped Call hedge no longer offsets dilution. Source: atom 0001801368-26-000029.
  • Maaden JV definitive formation documents: the November 2025 press release used "binding agreement" language but the same release listed execution of definitive JV formation documents as an open item (atom 0001193125-25-287046_ex99-1, context section). Have definitive documents been signed? Total capital cost, nameplate capacity, and construction timeline remain undisclosed in any available atom.
  • USAR litigation mechanics: the GBD trade-secrets suit (filed May 2026, Texas Business Court) seeks >$5M plus injunction against USAR. What is the realistic injunction path and timeline in Texas commercial courts? Does the suit constitute a durable competitive moat for MP's GBD technology, or is it primarily a signal-of-seriousness filing?
  • Unnamed NdPr offtake counterparty (Feb 2026): the Q1 2026 10-Q discloses an NdPr supply agreement with "a leading U.S. technology and industrial company" at an undisclosed volume (atom 0001801368-26-000029, reported_results[61]). Has the counterparty been publicly identified in subsequent disclosures? The redaction suggests size or strategic sensitivity.

Decision log

  • 2026-05-12: Wiki page created. probe position established. Thesis validation gate: separation facility commissioning mid-2026.
  • 2026-05-20: Reclassified probe-treated T2 -> T2 High Conviction with a formal scale-up mandate (MP Policy v0.1, PORTFOLIO_CONTEXT.md), in the Tranche & Policy Review session. Driven by the DoW masses-layer research. Hybrid accumulation: initial slice authorized now toward a near-term floor; larger tranche toward a ceiling gated on the mid-2026 separation-facility commissioning. Anchor is the trajectory destination. See the Reclassification banner at the top of this page.
  • 2026-05-20: COO Michael Rosenthal insider buy: 17,000 sh @ $56.62 (direct account). Form 4 accession 0001832050-26-000005. Operating-level conviction at prices consistent with the position's cost basis (see data/cost_basis.json).
  • 2026-05-22: Initial scale-in GTC cancelled -- price ran from ~$55 to ~$64 on the China REE export-control catalyst, running past the no-chase guard (MP Policy v0.1, project/docs/PORTFOLIO_CONTEXT.md). Per policy, no add above ~$68 absent a fresh thesis-upgrading catalyst; the initial-slice GTC stood down. SAIC prune proceeds redeployed to LEU T3 scaling per the Offense Priority List. The position size is unchanged; scale-up now rests on the gated tranche (HREE commissioning). See also USAR lawsuit (separate 2026-05-22 event below).
  • 2026-05-22: MP Materials filed suit in the Business Court of Texas against USA Rare Earth (USAR), ex-MP engineer Kevin Elkins, and FOM Technologies over grain-boundary-diffusion (GBD) magnet trade secrets; seeks >$5M plus injunction. USAR filed a denial June 2026. IP validation signal; moderate litigation overhang. Source: 2026-06-25 scout pass (The Oklahoman Post, 2026-05-28).
  • 2026-06-09: AGM (8-K accession 0001801368-26-000035): directors Arnold Donald and Randall Weisenburger elected through 2029; say-on-pay ~22.7% dissent (mildly elevated); KPMG ratified. No material governance changes. COO Rosenthal second insider buy: 10,000 sh @ $54.30 (family trust). Form 4 accession 0001832050-26-000007. Combined COO buys: ~$1.5M in 37 days at prices consistent with the position cost basis.
  • 2026-06-22: China MOFCOM added MP Materials to its export-control entity list (alongside USAR and 8 others) -- bars Chinese exporters from supplying dual-use items to MP; stated retaliation for Pentagon's military-entities list additions. Assessed operational impact: minimal (China sales ceased July 2025). BofA reiterated Buy, $85 PT (at 2026-06-22). Stock: ~$58-61 area -> ~$55-56 on the news. No thesis-break; state-dependence delta noted in Risks. Sources: Al Jazeera 2026-06-22; FDD 2026-06-24.
  • 2026-06-25: Wiki refreshed. Position records reconciled against data/cost_basis.json (entry date corrected from "May 2026" to ~November 2025 per the broker-verified 2025-11-21 lot date, Mike-confirmed); open questions updated (DoD conversion answered, NdPr-vs-floor answered); Catalysts / Triggers / Risks updated for June 2026 developments; live cost-basis-proxy and share-count leaks removed from the public banner and decision log. Recorded at refresh, not backdated.